Literature DB >> 34298399

Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ.

Urban Švajger1, Nataša Tešić2, Primož Rožman2.   

Abstract

Interferon-γ (IFN-γ) is the sole representative of type II IFNs, with well recognized role in numerous inflammatory processes. Lately, its significant pleiotropic nature has been recognized in many scenarios, where IFN-γ contributes to maintenance or induction of tolerogenic responses in context of various immune cell types. In this manuscript we demonstrate, that IFN-γ-mediated induction of programmed death ligand 1 (PD-L1) on human monocyte-derived dendritic cells (DCs) represents an important tolerogenic aspect in immunological network of type II IFNs. When fully differentiated, immature DCs were treated with increasing concentrations of IFN-γ there was no sign of maturation, as revealed by CD80, CD83 and CD86 expression. In terms of co-stimulatory receptor response, we did observe a dose-dependent increase in CD40 expression. Phenotypic analysis of inhibitory molecules revealed that PD-L1 expression is particularly sensitive to IFN-γ, as its expression can be induced almost 10-fold in comparison to non-treated DCs. Functional analysis of such PD-L1high DCs revealed significant immunosuppressive properties in a mixed lymphocyte reaction with whole or memory CD4+ T cells. When IFN-γ treated DCs were co-cultured with naive CD4+CD45RA+ T cells, they induced an increased percentage of CD4+CD25+CD127-FoxP3+ Tregs. Inhibition of PD-1/PD-L1 axis using neutralizing anti-PD-L1 mAbs, reversed the immunosuppressive effect of IFN-γ-treated DCs to suppress CD4+ T cell proliferation and to induce Tregs. In summary, our findings demonstrate the importance of IFN-γ-mediated tolerogenic effects, exerted on DCs by inducing increased expression of PD-L1, which enhances their regulatory function.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Interferon gamma; Programmed death ligand 1; Regulatory T cells; Tolerogenic

Mesh:

Substances:

Year:  2021        PMID: 34298399     DOI: 10.1016/j.intimp.2021.107978

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  3 in total

1.  A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.

Authors:  Jie Peng; Dan Zou; Lijie Han; Zuomin Yin; Xiao Hu
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

2.  CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer.

Authors:  Claire Olingy; Ahmad Alimadadi; Daniel J Araujo; David Barry; Norma A Gutierrez; Max Hardy Werbin; Edurne Arriola; Sandip Pravin Patel; Christian H Ottensmeier; Huy Q Dinh; Catherine C Hedrick
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

Review 3.  Exercise as a Peripheral Circadian Clock Resynchronizer in Vascular and Skeletal Muscle Aging.

Authors:  Bruna Spolador de Alencar Silva; Juliana Souza Uzeloto; Fábio Santos Lira; Telmo Pereira; Manuel J Coelho-E-Silva; Armando Caseiro
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.